Travere Therapeutics, Inc. ((TVTX)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Travere Therapeutics, Inc. is conducting a clinical study titled ‘A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)’. The study aims to assess the safety and efficacy of sparsentan tablets in treating proteinuria in patients who have undergone kidney transplantation, with a focus on IgAN and FSGS conditions.
The intervention being tested is sparsentan, a non-immunosuppressive drug with dual antagonism of ETAR and AT1R. It is designed to reduce proteinuria in patients with kidney diseases such as IgAN and FSGS.
This is a Phase 4 interventional study with an open-label, single-group design. There is no masking involved, and the primary purpose is treatment. The study will span 46 weeks across multiple centers.
The study began on October 9, 2025, with the last update submitted on October 21, 2025. These dates are crucial as they mark the recruitment phase and the latest information available on the study’s progress.
This update from Travere Therapeutics could influence investor sentiment positively, as successful results might boost the company’s stock performance. The study’s focus on a niche market with limited treatment options could position Travere favorably against competitors.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.